Antiproliferative activity and QSAR study of copper(II) mixed chelate [Cu(N–N)(acetylacetonato)]NO3 and [Cu(N–N)(glycinato)]NO3 complexes, (Casiopeínas®)-Reference-Cited by-同舟云学术

Antiproliferative activity and QSAR study of copper(II) mixed chelate [Cu(N–N)(acetylacetonato)]NO3 and [Cu(N–N)(glycinato)]NO3 complexes, (Casiopeínas®)

Published:2009-02 Issue:2 Volume:103 Page:299-309
ISSN:0162-0134
Container-title:Journal of Inorganic Biochemistry
language:en
Short-container-title:Journal of Inorganic Biochemistry

Author:

Bravo-Gómez María Elena,García-Ramos Juan Carlos,Gracia-Mora Isabel,Ruiz-Azuara Lena

Publisher

Elsevier BV

Subject

Inorganic Chemistry,Biochemistry

Reference76 articles.

1. The Biological Chemistry of the Elements – The Inorganic Chemistry of Life;Fraústo da Silva,1991

2. Anticancer metal compounds in NCI's tumor-screening database: putative mode of action

3. Metal Compounds in Cancer Therapy;Fricker,1994

4. Copper toxicity, oxidative stress, and antioxidant nutrients

5. L. Ruiz-Azuara, United States Patent 1992, vol. RE 35,458, February 18, 1997.

Cited by 195 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis, crystal structure and cytotoxic activity of 2,2′-bipyridine / 1,10-Phenanthroline based Copper(II) complexes with diphenylphosphinic acid;Polyhedron;2024-10

2. Doble synergetic anticancer activity through a combined chemo-photodynamic therapy and bioimaging of a novel Cas-ZnONPs all-in-one system;Journal of Inorganic Biochemistry;2024-09

3. Antitumoral and Antimetastatic Activity by Mixed Chelate Copper(II) Compounds (Casiopeínas®) on Triple-Negative Breast Cancer, In Vitro and In Vivo Models;International Journal of Molecular Sciences;2024-08-13

4. Copper(ii) Complexes Based on 2,2’-Bipyridine and 1,10-Phenanthroline as Potential Objects for Developing Antitumor Drugs;Journal of Structural Chemistry;2024-06

5. L-Citrullinato-Bipyridine and L-Citrullinato-Phenanthroline Mixed Copper Complexes: Synthesis, Characterization and Potential Anticancer Activity;Pharmaceutics;2024-05-31